Skip to content

Quick ratio at other companies

Amgen logo
AmgenAMGN
+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-1.1×
Gilead Sciences logo
Gilead SciencesGILD
1.7×+0.5×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
3.2×-0.5×
Nuvation Bio logo
Nuvation BioNUVB
7.2×-1.8×

Other financials

Income statement

See full
Revenue-$29.0K-101%
Gross profit$1.2M-60.2%
Operating income-$132.3M+5.2%
Net income-$125.7M-3.9%
EPS (diluted)-$0.85+3.4%

Balance sheet

See full
Cash & equivalents$283.0M-23.1%
Total debt$95.6M-0.5%
Total equity$812.8M-22.1%
Total assets$1.0B-21.6%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$390.0K-76.1%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.71B+61.1%
Enterprise value$1.53B+102%
P/S26.2×-24.8×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-720.8%-313pp
Net margin-676%-291pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-47.7%+3.6pp
Debt / equity0.1×0.0×
Current ratio7.1×+0.3×

Where this comes from

Calculated from Vir Biotechnology, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vir Biotechnology, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vir Biotechnology, Inc.'s quick ratio?
Vir Biotechnology, Inc. (VIR) reported quick ratio of 7.1× in Q1 2026.
How has Vir Biotechnology, Inc.'s quick ratio changed year-over-year?
Vir Biotechnology, Inc.'s quick ratio increased by 4.7% year-over-year, from 6.8× to 7.1×.
What is the long-term trend for Vir Biotechnology, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s quick ratio has grown at a -6.6% compound annual growth rate (CAGR), from 7.8× to 5.5×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.